In this article, I seek to update what''s happened to the Medical Care wing with the FMS symbol. Read more about Fresenius Medical Care here.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 21.03.2023 / 10:54 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 21.03.2023 / 10:54 CET/CEST The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Title: Dr. First name: Katarzyna Last name(s): Mazur-Hofsäß 2. Reason for the notification a) Position / status Position: Member of the managing body b) Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Fresenius Medical Care AG & Co. KGaA b) LEI 549300CP8NY40UP89Q40 4. Details of the transaction(s) a) Description of the financial instrument, type of instrument, identification code Type: Share ISIN: DE0005785802 b) Nature of the transaction Acquisition c) Price(s) and volume(s) Price(s) Volume(s) 36.81 EUR 4,822.11 EUR 36.81 EUR 331.29 EUR 36.81 EUR 1,104.30 EUR 36.82 EUR 1,215.06 EUR 36.82 EUR 3,461.08 EUR d) Aggregated information Price Aggregated volume 36.8143 EUR 10,933.8400 EUR e) Date of the transaction 2023-03-16; UTC+1 f) Place of the transaction Name: CBOE Europe MIC: CCXE 21.03.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

The Principal, King’s College Lagos, Mr Andrew Ali Agada, has appealed to the Federal Ministry of Education (FME) to find ways of collaborating with its sports counterpart in harnessing and developing talents discovered at the end of every sporting competition of various schools. The post Principal urges synergy between FME, sports in talent identification appeared first on The Guardian Nigeria News - Nigeria and World News .

Fresenius Medical Care AG & Co. KGaA / Preliminary announcement on the disclosure of financial statements Fresenius Medical Care AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] 16.03.2023 / 14:05 CET/CEST Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Fresenius Medical Care AG & Co. KGaA hereby announces that the following financial reports shall be disclosed: Report Type: Annual financial report Language: German Date of disclosure: March 23, 2023 Address: http://www.freseniusmedicalcare.com/de/investoren/publikationen Language: English Date of disclosure: March 23, 2023 Address: http://www.freseniusmedicalcare.com/en/investors/publications Report Type: Annual financial report of the group Language: German Date of disclosure: March 23, 2023 Address: http://www.freseniusmedicalcare.com/de/investoren/publikationen Language: English Date of disclosure: March 23, 2023 Address: http://www.freseniusmedicalcare.com/en/investors/publications Report Type: Financial report of the group (half-year/Q2) Language: German Date of disclosure: August 04, 2023 Address: http://www.freseniusmedicalcare.com/de/investoren/publikationen Language: English Date of disclosure: August 04, 2023 Address: http://www.freseniusmedicalcare.com/en/investors/publications 16.03.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Fresenius Medical Care AG with ticker code (FMS) have now 3 analysts in total covering the stock. The consensus rating is ''Underperform''. The target price ranges between 31.48 and 11.66 calculating the mean target price we have 21.69. With the stocks previous close at 19.82 this would imply there is a potential upside of 9.4%. The 50 day MA is 18.39 and the 200 day moving average is 18.89. The company has a market capitalisation of $11,167m. You can visit the company''s website by visiting: https://www.freseniusmedicalcare.com [stock_market_widget type="chart" template="basic" color="green" assets="FMS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $12,221m based on the market concensus. Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient''s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

BERLIN — Defense contractor Rheinmetall will join Germany’s DAX index this month, Deutsche Boerse said on Friday, with increased defense spending due to the war in Ukraine bumping it up into the club of blue-chip companies. As part of the DAX revision, which will take effect on March 20, crisis-ridden dialysis group Fresenius Medical Care […]

BAD HOMBURG, Germany (AP) — BAD HOMBURG, Germany (AP) — Fresenius Medical Care AG (FMS) on Tuesday reported fourth-quarter earnings…

Fresenius Medical Care AG & Co. KGaA (NYSE:NYSE:FMS) Q4 2022 Earnings Conference Call February 22, 2023 9:30 AM ETCompany ParticipantsDominik Heger - Head, Investor RelationsHelen Giza…

Fresenius Medical Care AG & Co (NYSE: FMS ) has implemented its new operating model with two global segments: Care Enablement (Health Care Products) and Care Delivery (Health Care Services), along with portfolio adjustment. In Care Delivery, the company will exit unsustainable markets and divest non-core businesses. In Care Enablement, it will rationalize its global R&D programs and evaluate the divestment of non-core products. The company will strictly follow its policy to align dividend payments with earnings development. This year''s dividend proposal of €1.12 reflects a reduction … Full story available on Benzinga.com

The following slide deck was published by Fresenius Medical Care AG & Co.

Fresenius Medical Care AG - Consensus Indicates Potential .6% Upside

Fresenius Medical Care shares hit their highest level in nearly seven months on Wednesday, welcoming news that FMC parent Fresenius would cede control over the struggling dialysis firm but keep its stake for now as part of a turnaround plan.

Fresenius Medical Care (FMS) stock rose ~5% premarket on Wednesday after the company announced plans of restructuring and cost saving targets amid its Q4 results.Fresenius said it…

Companies Reporting Before The Bell • Rio Tinto (NYSE: RIO ) is projected to report earnings for its Fiscal Year 2022. • Fiverr International (NYSE: FVRR ) is projected to report quarterly earnings at $0.20 per share on revenue of $83.46 million. • Wix.com (NASDAQ: WIX ) is expected to report quarterly earnings at $0.09 per share on revenue of $351.98 million. • Fresenius Medical Care (NYSE: FMS ) is likely to report quarterly earnings at $0.24 per share on revenue of $5.20 billion. • PGT Innovations (NYSE: PGTI ) is likely to report quarterly earnings at $0.28 per share on revenue of $334.12 million. • Gibraltar Industries (NASDAQ: ROCK ) is estimated to report quarterly earnings at $0.73 per share on revenue of $334.73 million. • Installed Building Prods (NYSE: IBP ) is projected to report quarterly earnings at $2.16 per share on revenue of $676.69 million. • OneSpaWorld Holdings (NASDAQ: OSW ) is estimated to report quarterly earnings at $0.12 per share on revenue of $166.20 million.

Shares in Fresenius SE fell by 3.1% early Wednesday after the German healthcare group forecast a 2023 fall in profit partly due to plans to cede strategic control over dialysis group Fresenius Medical Care (FMC) .

BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius Medical Care AG & Co. KGaA (FMS), a German- American healthcare company, on Wednesday reported a decline in earnings for the fourth-quarter. The res…

German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the diversified healthcare group, it said.

EQS-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Strategic Company Decision Fresenius Medical Care AG & Co. KGaA initiates firm plans for change of the legal form into a German stock corporation 21-Feb-2023 / 19:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast/Strategic Company Decision Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft) 21-Feb-2023 / 19:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR

Fresenius SE & Co. KGaA / Key word(s): Forecast/Strategic Company Decision Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft) 21-Feb-2023 / 19:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius expects Group organic revenue (base 2022: €40,840 million) to grow in a low- to mid-single-digit percentage range. Group constant currency EBIT before special items (base 2022: €3,727 million*) is expected to remain broadly flat or decline up to a high-single-digit percentage rate.

Fresenius Medical Care (FMS) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open.The consensus EPS Estimate is $0.23 (-74.4% Y/Y) and the…

Fresenius Medical Care (NYSE: FMS ) is set to give its latest quarterly earnings report on Wednesday, 2023-02-22. Here''s what investors need to know before the announcement. Analysts estimate that Fresenius Medical Care will report an earnings per share (EPS) of $0.24. Fresenius Medical Care bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, … Full story available on Benzinga.com

Fresenius is expected to deconsolidate its subsidiary Fresenius Medical Care. Click here to read whether this warrants an upgrade to our rating on the stock.

German healthcare group Fresenius SE said on Thursday it was potentially ready to cede control over Fresenius Medical Care (FMC) , after a fall in earnings at the world''s largest dialysis company.

FRANKFURT — German healthcare group Fresenius SE said on Thursday it was potentially ready to cede control over Fresenius Medical Care (FMC), after a fall in earnings at the world’s largest dialysis company. Shares in FMC were down 3.4% at 1538 GMT, while Fresenius stock surged 4.3% after it said it was considering de-consolidating the […]

Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation 09-Feb-2023 / 16:26 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. B ad Homburg, February 9, 2023 Following press reports, Fresenius Medical Care AG & Co. KGaA (“Company”) confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company and which is the sole shareholder of the general partner Fresenius Medical Care Management AG, is reviewing the deconsolidation of the Company. This review includes a potential change of the legal form of the Company into a German stock corporation (Aktiengesellschaft). The review of the required measures by the Company continues and the necessary decisions of the competent bodies are still outstanding.

EQS-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation 09-Feb-2023 / 16:26 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Miscellaneous Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation 09-Feb-2023 / 16:24 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by

Fresenius SE & Co. KGaA / Key word(s): Miscellaneous Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation 09-Feb-2023 / 16:24 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“ the Issuer ”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“ FMC ”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft). The Else Kröner-Fresenius-Stiftung which holds all shares in the Issuer’s general partner has informed the Issuer that it has taken note with approval of the Issuer’s plans to deconsolidate FMC by way of a change of the legal form into a stock corporation.

WILMINGTON, DE / ACCESSWIRE / February 1, 2023 / Transparency Market Research Inc. - The global Catheter-related Bloodstream Infections Market size stood at US$ 1.3 Bn in 2021 and is expected to surpass the value of US$ 2.0 Bn by 2031. The market is anticipated to expand at a CAGR of 5.1% between 2022 and 2031. The global catheter-related bloodstream infections market value is driven by the increasing prevalence of chronic illnesses, the aging population, and the rise in the number of invasive medical operations. Growing demand for catheterization among patients is further anticipated to drive market demand. For market participants, the increase in the usage of cutting-edge technology and solutions for CRBSI infection prevention and treatment, including catheters with antimicrobial coatings and enhanced diagnostic techniques, is creating significant growth potential. Leading companies are putting efforts into developing advanced, safe, and affordable products. Government programs aimed at enhancing the safety of patients and raising awareness about CRBSIs amongst patients and healthcare professionals are projected to accelerate market development.

Fresenius Medical Care AG with ticker code (FMS) have now 3 analysts in total covering the stock. The consensus rating is ''Underperform''. The range between the high target price and low target price is between 31.47 and 11.65 with a mean TP of 20.02. With the stocks previous close at 18.87 this now indicates there is a potential upside of 6.1%. The day 50 moving average is 16.48 and the 200 day moving average is 20.33. The company has a market cap of $10,991m. Find out more information at: https://www.freseniusmedicalcare.com [stock_market_widget type="chart" template="basic" color="green" assets="FMS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $11,661m based on the market concensus. Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient''s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.